Reduction in the price of oncological drugs did not deter private providers from ADSE
An official source confirms that the new price list for oncological medicines, which took effect on 1 October, is being implemented without any private healthcare providers leaving the ADSE network.
Why it matters
If you are an ADSE beneficiary undergoing oncological treatment in private clinics, this confirms that your access to care under the current agreement remains stable despite recent price changes.
Your quick shot of what's changing in Portugal and affecting your status, your home, your money, and whatever might disrupt your day. Short and clear updates, gathered from Portuguese sources.
From 1 October, 48.2% of oncology drugs will require prior authorization from ADSE. This is a slight decrease from the current rate, where 50.6% of these medications require such approval under the existing price table.
A new analysis covering 2020-2025 data shows that innovative cancer drugs take an average of 926 days to reach patients in Portugal after European approval, significantly longer than the EU average of 655 days. The report also highlights that over half of surveyed patients (50.8%) have experienced at least one instance of being without medication due to stock shortages, and patients travel an average of 56 kilometers to access their treatment.
A new study reveals that the National Health Service (SNS) has no regular, systematic method for updating the prices it pays private clinics for diagnostic and therapeutic exams (MCDTs). Seven specialties, including physical medicine and rehabilitation, have seen no price adjustments since 2014, with others like clinical analysis seeing only modest changes. The study proposes a new methodology to address these pricing issues, noting that current updates are reactive, sporadic, and fail to account for regional cost differences.